Status:
COMPLETED
Treatment of Diabetes After Gastric Bypass With Sitagliptin
Lead Sponsor:
Blandine Laferrere
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
Detailed Description
Januvia (sitagliptin phosphate 100mg) is an FDA approved medication for the treatment of Type 2 Diabetes. Sitagliptin works by inhibiting the Dipeptidyl peptidase-4 enzyme, resulting in increased acti...
Eligibility Criteria
Inclusion
- Must be a resident of the NYC metropolitan area or be able to come for emergency unscheduled and regular weekly meetings in Manhattan.
- HbA1c ≥ 6.5% and ≤ 8.5 % or a fasting glucose ≥ 126 mg/dL or a random glucose ≥ 200 mg/dL at least 12 months after GBP surgery confirmed by central laboratory.
- Subject is capable and willing to give informed consent.
- Subject is otherwise in good general health, based on medical history and physical examination.
- Subject is a non smoker for at least 6 months prior to study start
- Female subjects of child bearing potential must use oral, injected or implanted hormonal methods of contraception from at least the commencement of their last normal period prior to the first administration of the challenge agent. Subjects using hormonal contraception should use a barrier method in addition from the first administration of challenge agent until their next normal period following the end of the study.
Exclusion
- History of type 1 diabetes
- Female subject is pregnant or breastfeeding.
- Recent (\< 30 days) or simultaneous participation in another clinical trial.
- Any situation that can compromise the study, including serious illness or a predictable lack of cooperation from the subject.
Key Trial Info
Start Date :
July 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT01512797
Start Date
July 1 2012
End Date
August 1 2016
Last Update
January 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Obesity Nutrition Research Center, Columbia University
New York, New York, United States, 10032